澳大利亚墨尔本性健康诊所未接种MSM年轻男性肛周HPV感染率
研究在澳大利亚墨尔本对496名20-26岁未接种HPV疫苗的男男性行为者(MSM)在接种首剂前检测肛周HPV。56.5%检出高危型HPV,43.1%检出至少一种四价疫苗可预防型别(6/11/16/18),21.0%检出HPV16。提示针对性补种HPV疫苗仍有益。
要点
- 20-26岁未接种MSM中高危型肛周HPV检出率56.5%
- 四价疫苗可预防型别检出率43.1%,HPV16为21.0%
- 该人群补种HPV疫苗仍可预防高危型感染
核心结论
- 针对性MSM补种HPV疫苗仍有助于预防与肛门癌相关的高危型HPV及低危型HPV感染。
研究设计与样本
- 研究纳入2017年在澳大利亚墨尔本性健康中心接种首剂HPV疫苗的496名20-26岁MSM,检测接种前肛周HPV。
主要发现
- 56.5%的MSM肛周检出任何高危型HPV。
- 43.1%的MSM检出至少一种四价HPV疫苗可预防型别(6、11、16或18)。
- 21.0%的MSM肛周检出HPV16。
临床怎么用
- 对20-26岁未接种MSM评估肛周HPV感染风险并推荐HPV疫苗接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Victorian Government introduced a time-limited quadrivalent human papillomavirus (HPV) vaccination catch-up program targeting gay and bisexual men who have sex with men (MSM) aged up to 26 years in 2017. As of 2017, men aged ≥20 years were not eligible for the school-based HPV vaccination program. This study examined the prevalence of anal HPV among 496 MSM aged 20-26 years before they received the first dose of the HPV vaccine at the Melbourne Sexual Health Centre, Australia. More than half (56.5%) had any high-risk HPV genotypes detected in the anus. Almost half (43.1%) had at least one quadrivalent HPV vaccine-preventable genotype (6, 11, 16 or 18) and one-fifth (21.0%) had HPV 16 detected in the anus. These findings suggest that a targeted catch-up HPV vaccination program for MSM is still beneficial to protect against high-risk HPV genotypes associated with anal cancer, as well as low-risk HPV genotypes.
引用
- Chow EPF, Danielewski JA, Murray GL, et al. Anal human papillomavirus infections in young unvaccinated men who have sex with men attending a sexual health clinic for HPV vaccination in Melbourne, Australia. Vaccine. 2019. PMID: 31521414. doi:10.1016/j.vaccine.2019.08.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。